A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
NCT #
NCT05394103
Condition(s)
Breast, Colorectal, Ovarian, Pancreatic, Prostate, small-cell lung
Molecular Target(s)
CDK7
Drug Classification(s)
Small Molecule
Agents(s)
Q901
Phase(s)
I/II
Mechanism of Action
Q901 is a small molecule inhibitor for CDK7 kinase activity, thereby inhibiting CDK7-mediated signaling. Inhibition of CDK7 may inhibit tumor cell proliferation via inhibiting cell cycle progression, such as CDK1, 2, 4 and 6.
Purpose
- How much of the study can be given with an acceptable level of side effects
- The effects of the study (good and bad)
- The dose of the study drug that should be used in future studies
- How much of the study is absorbed into the blood and how fast it is removed
- How the study is acting on your body
- Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit
- Measurable disease per RECIST v 1.1
- ECOG performance status 0,1 or 2
- Life expectancy of at least 3 months
- New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary/peripheral artery bypass graft, congestive heart failure within the past 6 months
- Have a corrected QT interval (using Fridericia’s correction formula) (QTcF) of >470 msec (females) and >450 msec (males)
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Active, poorly controlled autoimmune or inflammatory diseases
No restrictions
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
UC23-03
N/A
n/a
N/A
Prostate
UCNT
UC23-02
Potent, highly selective, allosteric, orally bioavailable, small molecule inhibitor ofPRC2 via binding the embryonic ectoderm development (EED) subunit
Small Molecule
Not Required
Prostate
UCNT
MCLA-128-CL01
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
n/a
NRG1 fusion
Non-Small Cell Lung, Pancreatic
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.